Loading...
*  Neoadjuvant Treatment in Resectable Pancreatic Cancer - Full Text View - ClinicalTrials.gov
Disease-free Survival [ Time Frame: three years ]. Median disease-free survival (DFS, local and distant), overall survival (OS) ... Digestive System Diseases. Pancreatic Diseases. Endocrine System Diseases. Gemcitabine. Antimetabolites, Antineoplastic. ... local and distant disease-free and global survival, and first site of tumor recurrence constitute further essential endpoints ... Disease progression during neoadjuvant therapy [ Time Frame: three months ]. Rate of patients with disease progression during ...
  https://clinicaltrials.gov/show/NCT01900327
*  Chapter 85. Neoadjuvant Chemotherapy | Kuerer's Breast Surgical Oncology | AccessSurgery | McGraw-Hill Medical
Locoregional treatment (mastectomy rate). B. Overall survival. C. Disease-free survival. (Reproduced, with permission, from ... Get Free Access Through Your Institution Contact your institution's library to ask if they subscribe to McGraw-Hill Medical ... this has not been associated with an increase in survival in most trials to date (Figs. 85-1B and 85-1C). In contrast, a major ... as well as the molecular phenotype of the residual disease for subsequent treatment planning. ...
  http://accesssurgery.mhmedical.com/content.aspx?bookid=428§ionid=39936217
*  Perioperative Therapy for Resectable Pancreatic Cancer - Full Text View - ClinicalTrials.gov
Kaplan-Meier estimate of overall survival at 5 years. *Median Recurrence Free Survival Following Pancreaticoduodenectomy [ Time ... Digestive System Diseases. Pancreatic Diseases. Endocrine System Diseases. Gemcitabine. Capecitabine. Oxaliplatin. ... To determine the median recurrence free survival following pancreaticoduodenectomy.. III. To determine the clinical response ... Condition or disease Intervention/treatment Phase Adenocarcinoma of the Pancreas Stage IA Pancreatic Cancer Stage IB Pancreatic ...
  https://clinicaltrials.gov/show/NCT00609336
*  How long do people usually live with untreated breast cancer - Things You Didn't Know
Everyone's different: Survival rates are most appropriately applied to large groups of patients; it's impossible to give such a ... Depends: This depends on the health of the patient before the diagnosis and also the stage of the disease. ...Read more ... A percentage of these women with systemic disease will succumb to the ca if it takes over a vital organ. ...Read more ... With treatment the 5 year survival rate for Stage I cancer is very high. Without treatment it would depend on the type of ...
  https://www.healthtap.com/topics/how-long-do-people-usually-live-with-untreated-breast-cancer
*  Metastatic breast cancer - Wikipedia
... the extent of the extra-cranial metastatic disease, and the treatment applied). The mean 1-year survival is estimated at 20%. ... There is free peer support and an online platform to interact with others going through various therapies, including Abraxane. ... Mean survival from diagnosis of a brain metastasis varies between studies, ranging from 2 to 16 months (depending on ... Metastatic disease to the liver causes jaundice, elevated liver enzymes, abdominal pain, loss of appetite, nausea, and vomiting ...
  https://en.wikipedia.org/wiki/Metastatic_breast_cancer
*  ERCC1 as a biomarker for bladder cancer patients likely to benefit from adjuvant chemotherapy | BMC Cancer | Full Text
Disease-free survival, ERCC1 expression, and adjuvant chemotherapy. The 2-year disease-free survival rates for ERCC1-positive ... Disease-free survival was defined from the day of operation to documented diseased recurrence or death from any cause. Patients ... Disease-free survival. Without adjuvant chemotherapy (a), with adjuvant chemotherapy (b) (interaction P = 0.20). ... and by disease-free survival (test for interaction, P = 0.20). ... showed borderline significance for disease-free survival (P = ...
  https://bmccancer.biomedcentral.com/articles/10.1186/1471-2407-12-187
*  Breast cancer classification - Wikipedia
... which estimate disease outcomes such as disease-free or overall survival in the absence of therapy, or true predictive factors ... The main stages are: Stage 0 which is in situ disease or Paget's disease of the nipple. Stage 0 is a pre-cancerous or marker ... TX refers to an inability to assess that site; Tis refers to DCIS, LCIS, or Paget's disease; T4d refers to inflammatory breast ... There is some nuance to the official definitions for N0 disease, which includes N0(i+) which refers to Isolated Tumor Cell ...
  https://en.wikipedia.org/wiki/Breast_cancer_classification
*  Vaccine Increases Disease-Free Survival for Follicular Lymphoma Patients | MD Anderson Cancer Center
Vaccine Increases Disease-Free Survival for Follicular Lymphoma Patients. MD Anderson News Release 05/31/2011 ... A lymphoma vaccine uniquely tailored for each patient extends disease-free survival by 14 months, with signs of an even better ... extending disease-free survival time from 28.7 months to 52.9 months. While those results need to be confirmed in randomized ... "Survival of follicular lymphoma patients has improved with newer types of chemotherapy, but advanced-stage disease still is ...
  https://www.mdanderson.org/newsroom/2011/05/vaccine-increases-disease-free-survival-for-follicular-lymphoma-.html
*  BRAFV600E Mutation is Associated with Decreased Disease-Free Survival in Papillary Thyroid Cancer | SpringerLink
22 %, p , 0.001). Five-year disease-free survival was 89.6 % for BRAFV600E positive and 96.3 % for negative tumours, p , 0.001 ... The primary outcome measure was disease-free survival. Secondary outcome measures were tumour size, nodal positivity and ... BRAFV600E Mutation is Associated with Decreased Disease-Free Survival in Papillary Thyroid Cancer. ... extra-thyroidal extension and reduced disease-free survival. It is an additional useful prognostic biomarker. ...
  https://link.springer.com/article/10.1007/s00268-016-3534-x
*  Survival and disease-free survival by breast density and phenotype in interval breast cancers | Cancer Epidemiology, Biomarkers...
Survival and disease-free survival by breast density and phenotype in interval breast cancers. Maria Sala, Laia Domingo, Javier ... Survival and disease-free survival by breast density and phenotype in interval breast cancers ... Background:We aimed to evaluate survival and disease-free survival in different subtypes of interval cancers by breast density ... Survival and disease-free survival by breast density and phenotype in interval breast cancers ...
  http://cebp.aacrjournals.org/content/early/2018/05/31/1055-9965.EPI-17-0995
*  Neratinib Improves Disease-Free Survival in Early-Stage HER2-Positive Breast Cancer - The ASCO Post
Neratinib Improves Disease-Free Survival in Early-Stage HER2-Positive Breast Cancer. By Chase Doyle and Caroline Helwick. ... "ExteNET is the first study to show a statistically significant improvement in invasive disease-free survival in the intent-to- ... ExteNet's primary analysis was the invasive disease-free survival for all patients treated who had completed 2 years of follow- ... 2. Chan A, Martin M, Von Minckwitz G, et al: Invasive disease-free survival benefit following neratinib as extended adjuvant ...
  http://www.ascopost.com/issues/november-25-2015/neratinib-improves-disease-free-survival-in-early-stage-her2-positive-breast-cancer/
*  Smoking Linked to Shorter Disease-free Survival in Stage III Colon Cancer - The ASCO Post
... with significantly poorer disease-free survival observed for current vs never-smokers with BRAF wild-type disease (HR = 1.60, ... there was evidence of poorer disease-free survival for smokers vs nonsmokers with KRAS mutant disease. Among patients with KRAS ... Disease-free Survival in Ever-smokers. Median follow up in patients not experiencing events was 3.5 years. On unadjusted ... However, disease-free survival was significantly poorer for ever-smokers vs never-smokers who were male (HR = 1.33, 95% CI = ...
  http://www.ascopost.com/issues/june-10-2013/smoking-linked-to-shorter-disease-free-survival-in-stage-iii-colon-cancer/
*  Virtual HDR CyberKnife SBRT for localized prostatic carcinoma: 5-Year disease-free survival and toxicity observations - Abstract
... distant metastasis-free survival was 100 and 95% by risk-group, and disease-specific survival was 100%. Acute and late grade 2 ... CONCLUSION: Virtual HDR prostate SBRT creates a very low PSA nadir, a high rate of 5-year disease-free survival and an ... Virtual HDR CyberKnife SBRT for localized prostatic carcinoma: 5-Year disease-free survival and toxicity observations - ... biochemical-relapse-free survival was 100 and 92% for low-risk and intermediate-risk patients, respectively, by ASTRO ...
  https://www.urotoday.com/recent-abstracts/urologic-oncology/prostate-cancer/78241-virtual-hdr-cyberknife-sbrt-for-localized-prostatic-carcinoma-5-year-disease-free-survival-and-toxicity-observations-abstract.html
*  Antibody-Targeted Chemotherapy-Induced Remission and Stem Cell Transplantation Prolong Disease-Free Survival for Leukemia...
... have prolonged disease-free survival following stem cell transplantation according to research presented today at the annual ... Antibody-Targeted Chemotherapy-Induced Remission and Stem Cell Transplantation Prolong Disease-Free Survival for Leukemia ... Antibody-Targeted Chemotherapy-Induced Remission and Stem Cell Transplantation Prolong Disease-Free Survival for Leukemia ... have prolonged disease-free survival following stem cell transplantation according to research presented today at the annual ...
  https://www.fredhutch.org/en/news/releases/2000/12/ASH_Mylotarg.html
*  Prognostic Factors on the Graft-versus-Host Disease-Free and Relapse-Free Survival after Adult Allogeneic Hematopoietic Stem...
S. G. Holtan, T. E. DeFor, A. Lazaryan et al., "Composite end point of graft-versus-host disease-free, relapse-free survival ... Prognostic Factors on the Graft-versus-Host Disease-Free and Relapse-Free Survival after Adult Allogeneic Hematopoietic Stem ... A. Jalali, K. Alimoghaddam, M. Mahmoudi et al., "The EBMT risk score in the presence of graft versus host disease in allogeneic ... P. Ljungman, M. Hakki, and M. Boeckh, "Cytomegalovirus in hematopoietic stem cell transplant recipients," Infectious Disease ...
  https://www.hindawi.com/journals/sci/2016/5143071/ref/
*  Effect of Trastuzumab on Disease Free Survival in Early Stage HER2-Negative Breast Cancer Patients With ERBB2 Expressing...
A Phase II Randomized Trial Evaluating the Effect of Trastuzumab on Disease Free Survival in Early Stage HER2-Negative Breast ... Effect of Trastuzumab on Disease Free Survival in Early Stage HER2-Negative Breast Cancer Patients With ERBB2 Expressing ... to these patients may result in the elimination of HER2 expressing disseminated tumor cells and improved disease free survival. ... Breast Diseases. Skin Diseases. Paclitaxel. Docetaxel. Liposomal doxorubicin. Albumin-Bound Paclitaxel. Cyclophosphamide. ...
  https://clinicaltrials.gov/ct2/show/NCT01779050
*  Renal-Cell Cancer Disease-Free Survival Up With Sunitinib | Physician's Weekly for Medical News, Journals & Articles
Renal-Cell Cancer Disease-Free Survival Up With Sunitinib by Logan Thomison , Oct 11, 2016 , 0 comments ... The researchers found that the median duration of disease-free survival was 6.8 and 5.6 years in the sunitinib and placebo ... 11, 2016 (HealthDay News) - The duration of disease-free survival is increased with sunitinib treatment for patients with ... the median duration of disease-free survival was significantly longer in the sunitinib group than in the placebo group, at a ...
  https://www.physiciansweekly.com/renal-cell-cancer-disease-free-survival-up-with-sunitinib/
*  Disease-free survival was estimated using the Kaplan-Me | Open-i
Disease-free survival was estimated using the Kaplan-Meier method anddefined as the period between diagnosis and local or ... f01: Disease-free survival was estimated using the Kaplan-Meier method anddefined as the period between diagnosis and local or ... f01: Disease-free survival was estimated using the Kaplan-Meier method anddefined as the period between diagnosis and local or ... and its association with prognostic factors and disease-free survival. Martins DM, Vidal FC, Souza RD, Brusaca SA, Brito LM - ...
  https://openi.nlm.nih.gov/detailedresult.php?img=PMC4230293_1414-431X-bjmbr-47-11-01008-gf001&req=4
*  Epigenetic Inactivation of microRNA-34b/c Predicts Poor Disease-Free Survival in Early-Stage Lung Adenocarcinoma | Clinical...
Epigenetic Inactivation of microRNA-34b/c Predicts Poor Disease-Free Survival in Early-Stage Lung Adenocarcinoma. Ernest Nadal ... Patients with increased miR-34b/c methylation had significantly shorter disease-free and overall survival as compared to ... Epigenetic Inactivation of microRNA-34b/c Predicts Poor Disease-Free Survival in Early-Stage Lung Adenocarcinoma ... Epigenetic Inactivation of microRNA-34b/c Predicts Poor Disease-Free Survival in Early-Stage Lung Adenocarcinoma ...
  http://clincancerres.aacrjournals.org/content/early/2013/12/12/1078-0432.CCR-13-0736
*  Gene Polymorphisms in Cyclophosphamide Metabolism Pathway, Treatment-Related Toxicity, and Disease-Free Survival in SWOG 8897...
... and Disease-Free Survival in SWOG 8897 Clinical Trial for Breast Cancer. Song Yao, William E. Barlow, Kathy S. Albain, Ji-Yeob ... Adjuvant chemotherapy for early stage breast cancer patients has greatly improved both disease-free and overall survival by ... Nitric oxide synthase variants and disease-free survival among treated and untreated breast cancer patients in a Southwest ... Manganese superoxide dismutase polymorphism, treatment-related toxicity and disease-free survival in SWOG 8897 clinical trial ...
  http://clincancerres.aacrjournals.org/content/16/24/6169.long
*  Insulin-like Growth Factor 2 Expression Modulates Taxol Resistance and Is a Candidate Biomarker for Reduced Disease-Free...
... and reduced disease-free survival (P , 0.05).. Conclusions: IGF2 modulates Taxol resistance, and tumor IGF2 expression is a ... Growth Factor 2 Expression Modulates Taxol Resistance and Is a Candidate Biomarker for Reduced Disease-Free Survival in Ovarian ... Growth Factor 2 Expression Modulates Taxol Resistance and Is a Candidate Biomarker for Reduced Disease-Free Survival in Ovarian ... Growth Factor 2 Expression Modulates Taxol Resistance and Is a Candidate Biomarker for Reduced Disease-Free Survival in Ovarian ...
  http://clincancerres.aacrjournals.org/content/early/2010/05/13/1078-0432.CCR-09-3233
*  The Combination Of Weak Expression Of PRDX4 And Very High MIB-1 Labelling Index Independently Predicts Shorter Disease-free...
The disease-free survival (DFS) and disease-specific survival (DSS) were defined as the interval from the date of surgery to ... disease-free survival; DSS, disease-specific survival; ROC, receiver operating characteristic and SCC, squamous cell carcinoma. ... Kaplan-Meier curves of the disease-free survival (DFS) in patients with lung adenocarcinoma after surgery according to the ... Strong expression of polypeptide N-acetylgalactosaminyltransferase 3 independently predicts shortened disease-free survival in ...
  http://www.medsci.org/v15p1025.htm
*  Adjuvant Gefitinib Improves Disease-free Survival Among Patients With NSCLC - Cancer Therapy Advisor
Adjuvant Gefitinib Improves Disease-free Survival Among Patients With NSCLC. Share this content: *facebook ... Adjuvant EGFR inhibition with gefitinib improves disease-free survival (DFS) compared with chemotherapy among patients with ... Progression-Free Survival and Patient Quality of Life Are Not One and the Same ... While EGFR inhibition is a standard first-line therapy for patients with EGFR--mutant disease, it is unknown whether this ...
  http://www.cancertherapyadvisor.com/lung-cancer/lung-cancer-nsclc-adjuvant-gefitinib-improves-survival-dfs/article/709347/
*  A) Disease-free survival and overall survival for pati | Open-i
A) Disease-free survival and overall survival for patients undergoing total laparoscopic radical hysterectomy (TLRH) or ... Figure 2: (A) Disease-free survival and overall survival for patients undergoing total laparoscopic radical hysterectomy (TLRH ... Figure 2: (A) Disease-free survival and overall survival for patients undergoing total laparoscopic radical hysterectomy (TLRH ... Disease-free survival and overall survival for patients with early-stage cervical cancer undergoing TLRH or ARH, and with ...
  https://openi.nlm.nih.gov/detailedresult.php?img=PMC4554128_medi-94-e1264-g005&req=4
*  No Disease-Free Survival Benefit of Adjuvant Sunitinib or Sorafenib in High-Risk Nonmetastatic Renal Cell Carcinoma - The ASCO...
No Disease-Free Survival Benefit of Adjuvant Sunitinib or Sorafenib in High-Risk Nonmetastatic Renal Cell Carcinoma. By Matthew ... Disease-Free Survival Due to low conditional power for the primary endpoint, the Data Safety Monitoring Committee recommended ... Five-year disease-free survival was 54.3%, 54.0%, and 56.4%, respectively.. Among patients with clear cell histology ( ... The primary objective was to compare disease-free survival between each experimental group and placebo in the intention-to- ...
  http://www.ascopost.com/issues/may-25-2016/no-disease-free-survival-benefit-of-adjuvant-sunitinib-or-sorafenib-in-high-risk-nonmetastatic-renal-cell-carcinoma/